At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory ...

US flu activity declined steadily again last week, with rates of influenza-like illness (ILI) dropping further and staying ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its ...

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

The HHS chief, who has long argued that vaccines cause autism, dismissed the notion that "better diagnoses, better recognition, or changing diagnostic criteria" are driving up figures. Also, the CDC's ...